GlassScriptPhysician profile
John Robert Spurzem
NPI 1467489930
$6,189.92
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,055 · 2020: $555 · 2021: $873 · 2022: $1,959 · 2023: $748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $748.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $830.26 | 2019-2023 | Uptravi |
| Glaxosmithkline, LLC. | $675.98 | 2019-2023 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $552.80 | 2019-2023 | Ofev |
| Astrazeneca Pharmaceuticals LP | $458.16 | 2019-2022 | |
| Pfizer INC. | $446.89 | 2019-2023 | |
| United Therapeutics Corporation | $345.65 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $343.72 | 2019-2023 | Zerbaxa, Recarbrio |
| Insmed, INC. | $309.08 | 2019-2023 | Arikayce |
| Mallinckrodt Hospital Products INC. | $217.39 | 2020-2023 | Acthar |
| Takeda Pharmaceuticals U.S.A., INC. | $162.52 | 2022-2023 | Glassia |
| Gilead Sciences, INC. | $158.17 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $149.99 | 2019 | |
| Intuitive Surgical, INC. | $144.67 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $144.53 | 2019-2023 | |
| Chiesi USA, INC. | $135.44 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $125.00 | 2022 | |
| Abbvie INC. | $115.95 | 2019-2023 | Teflaro |
| Astellas Pharma US INC | $103.81 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $88.24 | 2019 | |
| Genzyme Corporation | $84.76 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $84.33 | 2021-2022 | |
| Philips North America LLC | $81.87 | 2019-2020 | |
| Genentech USA, INC. | $73.18 | 2019-2021 | |
| Electromed, INC. | $62.61 | 2022 | |
| Grifols USA, LLC | $58.79 | 2020-2023 | Prolastin-C Liquid |
| Tetraphase Pharmaceuticals, INC. | $41.50 | 2019-2020 | |
| La Jolla Pharmaceutical Company | $38.51 | 2019-2020 | |
| Vapotherm INC | $35.75 | 2020-2022 | |
| Mylan Specialty L.P. | $34.21 | 2019 | |
| Circassia INC. | $19.64 | 2019 | |
| Inari Medical, INC. | $18.85 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Portola Pharmaceuticals, LLC | $17.52 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.76 | 2019 | |
| Nestle Healthcare Nutrition INC. | $13.39 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Spurzem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.